查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1283964

代謝症候群的全球市場(2023年版):各適應症，各分子類型，各給藥途徑，各地區，各國分析，市場考察與預測(2018年～2028年)

Global Metabolic Syndrome Market (2023 Edition): Analysis By Indication (NASH, IRS, Hypercholesterolemia, Obesity Syndrome, Others), By Molecule Type, Route of Administration, By Region, By Country: Market Insights and Forecast (2018-2028)
出版日期: | 出版商: Azoth Analytics | 英文 270 Pages | 訂單完成後即時交付

價格

全球代謝症候群的市場規模，從2021年的225億美元到2028年末預計達289億美元，2024年～2028年預計以46.30％的年複合成長率成長。

本報告提供全球代謝症候群市場相關調查分析，市場規模與預測，地區和市場區隔的分析，產業趨勢等資訊。

目錄

第1章 市場背景

  • 範圍與產品預測
  • 摘要整理
  • 調查手法

第2章 策略性推薦事項

第3章 全球代謝症候群市場:成果與預測(2018年～2028年)

  • 對代謝症候群市場的宏觀經濟要素的影響的分析
  • COVID-19對代謝症候群市場的影響
  • 全球代謝症候群市場:生態系統分析
    • 代謝症候群的實況報導
    • 代謝症候群治療藥的開發平台分析
    • 全球肥胖統計(2022年)
    • 各主要的已上市的代謝症候群治療藥:NPV
    • 各主要的開發平台的代謝症候群治療藥:NPV
  • 全球代謝症候群市場:儀表板
  • 全球代謝症候群市場:市場金額的評估(2018年～2028年)
  • 全球代謝症候群市場區隔:各適應症
    • 全球代謝症候群市場概要:各適應症
    • 全球代謝症候群的市場規模:各胰島素抗性症候群(金額)(2018年～2028年)
    • 全球代謝症候群的市場規模:各高膽固醇症(金額)(2018年～2028年)
    • 全球代謝症候群的市場規模:各肥胖症候群(金額)(2018年～2028年)
    • 全球代謝症候群的市場規模:各非酒精性脂肪性肝炎(金額)(2018年～2028年)
    • 全球代謝症候群的市場規模:其他的各適應症(金額)(2018年～2028年)
  • 全球代謝症候群市場區隔:各分子類型
    • 全球代謝症候群市場概要:各分子類型
    • 全球代謝症候群的市場規模:各低分子(金額)(2018年～2028年)
    • 全球代謝症候群的市場規模:各蛋白質(金額)(2018年～2028年)
    • 全球代謝症候群的市場規模:各RNA/DNA(金額)(2018年～2028年)
    • 全球代謝症候群的市場規模:其他的各分子(金額)(2018年～2028年)
  • 全球代謝症候群市場區隔:各給藥途徑
    • 全球代謝症候群市場:各給藥途徑概要
    • 全球代謝症候群的市場規模:各口服(金額)(2018年～2028年)
    • 全球代謝症候群的市場規模:各皮下(金額)(2018年～2028年)
    • 全球代謝症候群的市場規模:其他的各給藥途徑(金額)(2018年～2028年)

第4章 全球代謝症候群市場，地區分析

  • 研究的地區的範圍

第5章 南北美洲的代謝症候群市場:成果與預測(2018年～2028年)

  • 南北美洲的代謝症候群市場:概述
  • 南北美洲的代謝症候群市場:市場規模和年複合成長率(2018年～2028年)
  • 南北美洲的代謝症候群市場:主要原因
  • 南北美洲的代謝症候群市場區隔:各適應症
    • 南北美洲的代謝症候群市場:各適應症概要
    • 南北美洲的代謝症候群的市場規模:各胰島素抗性症候群(金額)(2018年～2028年)
    • 南北美洲的代謝症候群的市場規模:各高膽固醇症(金額)(2018年～2028年)
    • 南北美洲的代謝症候群的市場規模:各肥胖症候群(金額)(2018年～2028年)
    • 南北美洲的代謝症候群的市場規模:各非酒精性脂肪性肝炎(金額)(2018年～2028年)
    • 南北美洲的代謝症候群的市場規模:其他的各適應症(金額)(2018年～2028年)
  • 南北美洲的代謝症候群市場區隔:各分子類型
    • 南北美洲的代謝症候群市場:各分子類型概要
    • 南北美洲的代謝症候群的市場規模:各低分子(金額)(2018年～2028年)
    • 南北美洲的代謝症候群的市場規模:各蛋白質(金額)(2018年～2028年)
    • 南北美洲的代謝症候群的市場規模:各RNA/DNA(金額)(2018年～2028年)
    • 南北美洲的代謝症候群的市場規模:其他的各分子(金額)(2018年～2028年)
  • 南北美洲的代謝症候群市場區隔:各給藥途徑
    • 南北美洲的代謝症候群市場:各給藥途徑概要
    • 南北美洲的代謝症候群的市場規模:各口服(金額)(2018年～2028年)
    • 南北美洲的代謝症候群的市場規模:各皮下(金額)(2018年～2028年)
    • 南北美洲的代謝症候群的市場規模:其他的各給藥途徑(金額)(2018年～2028年)
  • 南北美洲的代謝症候群市場區隔:各國
    • 美國的代謝症候群市場:市場規模和年複合成長率(2018年～2028年)
    • 加拿大的代謝症候群市場:市場規模和年複合成長率(2018年～2028年)
    • 其他的南北美洲的代謝症候群市場:市場規模和年複合成長率(2018年～2028年)

第6章 歐洲的代謝症候群市場:成果與預測(2018年～2028年)

  • 歐洲的代謝症候群市場:概述
  • 歐洲的代謝症候群市場:市場規模和年複合成長率(2018年～2028年)
  • 歐洲的代謝症候群市場:主要原因
  • 歐洲的代謝症候群市場區隔:各適應症
    • 歐洲的代謝症候群市場:各適應症概要
    • 歐洲的代謝症候群的市場規模:各胰島素抗性症候群(金額)(2018年～2028年)
    • 歐洲的代謝症候群的市場規模:各高膽固醇症(金額)(2018年～2028年)
    • 歐洲的代謝症候群的市場規模:各肥胖症候群(金額)(2018年～2028年)
    • 歐洲的代謝症候群的市場規模:各非酒精性脂肪性肝炎(金額)(2018年～2028年)
    • 歐洲的代謝症候群的市場規模:其他的各適應症(金額)(2018年～2028年)
  • 歐洲的代謝症候群市場區隔:各分子類型
    • 歐洲的代謝症候群市場:各分子類型概要
    • 歐洲的代謝症候群的市場規模:各低分子(金額)(2018年～2028年)
    • 歐洲的代謝症候群的市場規模:各蛋白質(金額)(2018年～2028年)
    • 歐洲的代謝症候群的市場規模:各RNA/DNA(金額)(2018年～2028年)
    • 歐洲的代謝症候群的市場規模:其他的各分子(金額)(2018年～2028年)
  • 歐洲的代謝症候群市場區隔:各給藥途徑
    • 歐洲的代謝症候群市場:各給藥途徑概要
    • 歐洲的代謝症候群的市場規模:各口服(金額)(2018年～2028年)
    • 歐洲的代謝症候群的市場規模:各皮下(金額)(2018年～2028年)
    • 歐洲的代謝症候群的市場規模:其他的各給藥途徑(金額)(2018年～2028年)
  • 歐洲的代謝症候群市場區隔:各國
    • 法國的代謝症候群市場:市場規模和年複合成長率(2018年～2028年)
    • 英國的代謝症候群市場:市場規模和年複合成長率(2018年～2028年)
    • 義大利的代謝症候群市場:市場規模和年複合成長率(2018年～2028年)
    • 西班牙的代謝症候群市場:市場規模和年複合成長率(2018年～2028年)
    • 德國的代謝症候群市場:市場規模和年複合成長率(2018年～2028年)
    • 其他的歐洲的代謝症候群市場:市場規模和年複合成長率(2018年～2028年)

第7章 亞太地區的代謝症候群市場:成果與預測(2018年～2028年)

  • 亞太地區的代謝症候群市場:概述
  • 亞太地區的代謝症候群市場:市場規模和年複合成長率(2018年～2028年)
  • 亞太地區的代謝症候群市場:主要原因
  • 亞太地區的代謝症候群市場區隔:各適應症
    • 亞太地區的代謝症候群市場:各適應症概要
    • 亞太地區的代謝症候群的市場規模:各胰島素抗性症候群(金額)(2018年～2028年)
    • 亞太地區的代謝症候群的市場規模:各高膽固醇症(金額)(2018年～2028年)
    • 亞太地區的代謝症候群的市場規模:各肥胖症候群(金額)(2018年～2028年)
    • 亞太地區的代謝症候群的市場規模:各非酒精性脂肪性肝炎(金額)(2018年～2028年)
    • 亞太地區的代謝症候群的市場規模:其他的各適應症(金額)(2018年～2028年)
  • 亞太地區的代謝症候群市場區隔:各分子類型
    • 亞太地區的代謝症候群市場:各分子類型概要
    • 亞太地區的代謝症候群的市場規模:各低分子(金額)(2018年～2028年)
    • 亞太地區的代謝症候群的市場規模:各蛋白質(金額)(2018年～2028年)
    • 亞太地區的代謝症候群的市場規模:各RNA/DNA(金額)(2018年～2028年)
    • 亞太地區的代謝症候群的市場規模:其他的各分子(金額)(2018年～2028年)
  • 亞太地區的代謝症候群市場區隔:各給藥途徑
    • 亞太地區的代謝症候群市場:各給藥途徑概要
    • 亞太地區的代謝症候群的市場規模:各口服(金額)(2018年～2028年)
    • 亞太地區的代謝症候群的市場規模:各皮下(金額)(2018年～2028年)
    • 亞太地區的代謝症候群的市場規模:其他的各給藥途徑(金額)(2018年～2028年)
  • 亞太地區的代謝症候群市場區隔:各國
    • 中國的代謝症候群市場:市場規模和年複合成長率(2018年～2028年)
    • 日本的代謝症候群市場:市場規模和年複合成長率(2018年～2028年)
    • 印度的代謝症候群市場:市場規模和年複合成長率(2018年～2028年)
    • 其他的亞太地區的代謝症候群市場:市場規模和年複合成長率(2018年～2028年)

第8章 中東、非洲的代謝症候群市場:成果與預測(2018年～2028年)

  • 中東、非洲的代謝症候群市場:概述
  • 中東、非洲的代謝症候群市場:市場規模和年複合成長率(2018年～2028年)
  • 中東、非洲的代謝症候群市場:主要原因
  • 中東、非洲的代謝症候群市場區隔:各適應症
    • 中東、非洲的代謝症候群市場:各適應症概要
    • 中東、非洲的代謝症候群的市場規模:各胰島素抗性症候群(金額)(2018年～2028年)
    • 中東、非洲的代謝症候群的市場規模:各高膽固醇症(金額)(2018年～2028年)
    • 中東、非洲的代謝症候群的市場規模:各肥胖症候群(金額)(2018年～2028年)
    • 中東、非洲的代謝症候群的市場規模:各非酒精性脂肪性肝炎(金額)(2018年～2028年)
    • 中東、非洲的代謝症候群的市場規模:其他的各適應症(金額)(2018年～2028年)
  • 中東、非洲的代謝症候群市場區隔:各分子類型
    • 中東、非洲的代謝症候群市場:各分子類型概要
    • 中東、非洲的代謝症候群的市場規模:各低分子(金額)(2018年～2028年)
    • 中東、非洲的代謝症候群的市場規模:各蛋白質(金額)(2018年～2028年)
    • 中東、非洲的代謝症候群的市場規模:各RNA/DNA(金額)(2018年～2028年)
    • 中東、非洲的代謝症候群的市場規模:其他的各分子(金額)(2018年～2028年)
  • 中東、非洲的代謝症候群市場區隔:各給藥途徑
    • 中東、非洲的代謝症候群市場:各給藥途徑概要
    • 中東、非洲的代謝症候群的市場規模:各口服(金額)(2018年～2028年)
    • 中東、非洲的代謝症候群的市場規模:各皮下(金額)(2018年～2028年)
    • 中東、非洲的代謝症候群的市場規模:其他的各給藥途徑(金額)(2018年～2028年)

第9章 市場動態

  • 對全球代謝症候群市場的市場動態的影響的評估
  • 促進因素
  • 阻礙因素
  • 趨勢

第10章 產業生態系統分析

  • 宏觀經濟要素的評估
  • 波特的五力分析

第11章 競爭定位

  • 企業的產品定位
  • 市場地位矩陣
  • 代謝症候群市場佔有率分析
  • 企業簡介
    • Novo Nordisk
    • Eli Lilly and Company
    • Takeda Pharmaceutical
    • Sanofi
    • AstraZeneca
    • Amgen
    • Merck Co., Inc.
    • Johnson & Johnson
    • Pfizer
    • Abbott

Executive Summary

Azoth Analytics has released a research report titled "Metabolic Syndrome Market (2023 Edition)" which provides a complete analysis of the global Metabolic Syndrome industry in terms of market segmentation By Indication (Insulin Resistance Syndrome, Hypercholesterolemia, Obesity Syndrome, Nonalcoholic steatohepatitis, Other Indications), By Molecule Type (Small Molecule, Protein, RNA/DNA, Other Molecules) and By Route of Administration (Oral, Subcutaneous, Other ROA) for the historical period of 2018-2022, the estimated year 2023 and the forecast period of 2024-2028.

The research study is global in nature and covers a detailed analysis of the market in the Americas (U.S., Canada, Rest of Americas), Europe (France, U.K, Italy, Spain, Germany, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), and the Middle East and Africa. Additionally, the research report presents data including market size, yearly growth & potential analysis, the competitive study of market players, investment opportunities, demand for future forecast, and so on.

The research study also assesses market growth indicators, restraints, supply and demand risk, and other important statistics, as well as a full assessment of current and future market trends that are relevant to the market evolution.

The Global Metabolic Syndrome Market is expected to generate USD 28.9 billion by the end of 2028, up from USD 22.5 billion in 2021. Metabolic syndrome is a complicated disorder characterized by a group of linked metabolic abnormalities that raise the risk of cardiovascular disease, type 2 diabetes, and other major health problems. It is a global health issue with significant public health implications. Central obesity, high blood pressure, dyslipidemia (abnormal lipid profile), and reduced metabolism of glucose are important components of metabolic syndrome. During the forecast period, 2024-2028, the Global Metabolic Syndrome market is expected to expand at a CAGR of 46.30%.

In addition, as the healthcare sector moves toward a more preventive and customized approach, there is a greater emphasis on early detection and management to reduce the risk of metabolic syndrome-related challenges. This pattern is likely to fuel demand for diagnostic tests, treatment options, and digital health solutions.

Companies are working on creating novel drugs that address many aspects of metabolic syndrome at the same time. This strategy seeks to enhance patient outcomes while reducing the need for multiple drugs. Furthermore, technological advances such as wearable gadgets and mobile applications have evolved to assist individuals in monitoring their health metrics and successfully managing their condition.

Among the Indication type, Insulin Resistance Syndrome holds the maximum share in the market. The global market for therapeutics of Insulin resistance Metabolic Syndrome is expected to grow in the coming years, driven by the increasing prevalence of Diabetes.

This study also provides a competitive landscape of the industry and profiles leading players in the Global Metabolic Syndrome Market including Novo Nordisk, Eli Lilly and Company, Takeda Pharmaceutical, Sanofi, AstraZeneca, Amgen, Merck Co., Inc., Johnson & Johnson, Pfizer, and Abbott. The company profiling includes critical information such as a business overview, Drug Molecule type and other products, key financials, and recent events and developments. Overall, the report provides a detailed overview of the Global Metabolic Syndrome Market, which will assist industry consultants, equipment manufacturers, existing players looking for expansion opportunities, new players looking for opportunities, and other stakeholders in aligning their market-centric strategies with current and expected future trends.

Scope of the Report:

  • The report analyses the Metabolic Syndrome Market by Value (USD Million).
  • The report presents the analysis of Metabolic Syndrome market for the historical period of 2018-2022, the estimated year 2023 and the forecast period of 2024-2028.
  • The report analyses the Metabolic Syndrome Market by Indication (Insulin Resistance Syndrome, Hypercholesterolemia, Obesity Syndrome, Nonalcoholic steatohepatitis, Other Indications).
  • The report analyses the Metabolic Syndrome Market by Molecule Type (Small Molecule, Protein, RNA/DNA, Other Molecules).
  • The report analyses the Metabolic Syndrome Market by Route of Administration (Oral, Subcutaneous, Other ROA).
  • The Global Metabolic Syndrome Market has been analysed by countries including the United States, Canada, United Kingdom, Germany, France, Italy, Spain, China, India and Japan.
  • The key insights of the report have been presented through the frameworks of SWOT and Porter's Five Forces Analysis. Also, the attractiveness of the market has been presented by region, by Metabolic Syndrome Type, by Metabolic Syndrome Form, and by Sales Channel.
  • Also, the major opportunities, trends, drivers and challenges of the industry have been analysed in the report.
  • The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include Novo Nordisk, Eli Lilly and Company, Takeda Pharmaceutical, Sanofi, AstraZeneca, Amgen,Merck Co., Inc., Johnson & Johnson, Pfizer, and Abbott.

Table of Contents

1. Market Background

  • 1.1 Scope and Product Outlook
  • 1.2 Executive Summary
  • 1.3 Research Methodology

2. Strategic Recommendations

3. Global Metabolic Syndrome Market: Historic and Forecast (2018-2028)

  • 3.1 Impact Analysis of Macro Economic Factors on Metabolic Syndrome Market
  • 3.2 Impact of COVID-19 on Metabolic Syndrome Market
  • 3.3 Global Metabolic Syndrome Market: Ecosystem Analysis
    • 3.3.1 Metabolic Syndrome Fact Sheet
    • 3.3.2 Pipeline Analysis of Metabolic Syndrome Therapeutics
    • 3.3.3 Global Obesity Statistics 2022, in Millions
    • 3.3.4 Top marketed Metabolic Syndrome Therapeutics by NPV, USDm
    • 3.3.5 Top pipeline Metabolic Syndrome Therapeutics by NPV, in USD Millions
  • 3.4 Global Metabolic Syndrome Market: Dashboard
  • 3.5 Global Metabolic Syndrome Market: Market Value Assessment, 2018-2028 (USD Million)
  • 3.6 Global Metabolic Syndrome Market Segmentation: By Indication
    • 3.6.1 Global Metabolic Syndrome Market, By Indication Type Overview
    • 3.6.2 Global Metabolic Syndrome Market Size, By Insulin Resistance Syndrome, By Value, 2018H-2028F (USD Million & CAGR)
    • 3.6.3 Global Metabolic Syndrome Market Size, By Hypercholesterolemia, By Value, 2018H-2028F (USD Million & CAGR)
    • 3.6.4 Global Metabolic Syndrome Market Size, By Obesity Syndrome, By Value, 2018H-2028F (USD Million & CAGR)
    • 3.6.5 Global Metabolic Syndrome Market Size, By Nonalcoholic steatohepatitis, By Value, 2018H-2028F (USD Million & CAGR)
    • 3.6.6 Global Metabolic Syndrome Market Size, By Other Indications, By Value, 2018H-2028F (USD Million & CAGR)
  • 3.7 Global Metabolic Syndrome Market Segmentation: By Molecule Type
    • 3.7.1 Global Metabolic Syndrome Market, By Molecule Type Overview
    • 3.7.2 Global Metabolic Syndrome Market Size, By Small Molecule, By Value, 2018H-2028F (USD Million & CAGR)
    • 3.7.3 Global Metabolic Syndrome Market Size, By Protein, By Value, 2018H-2028F (USD Million & CAGR)
    • 3.7.4 Global Metabolic Syndrome Market Size, By RNA/DNA, By Value, 2018H-2028F (USD Million & CAGR)
    • 3.7.5 Global Metabolic Syndrome Market Size, By Other Molecules, By Value, 2018H-2028F (USD Million & CAGR)
  • 3.8 Global Metabolic Syndrome Market Segmentation: By Route of Administration
    • 3.8.1 Global Metabolic Syndrome Market, By Route of Administration Overview
    • 3.8.2 Global Metabolic Syndrome Market Size, By Oral, By Value, 2018H-2028F (USD Million & CAGR)
    • 3.8.3 Global Metabolic Syndrome Market Size, By Subcutaneous, By Value, 2018H-2028F (USD Million & CAGR)
    • 3.8.4 Global Metabolic Syndrome Market Size, By Other ROA, By Value, 2018H-2028F (USD Million & CAGR)

4. Global Metabolic Syndrome Market, Region Analysis

  • 4.1 Regional Coverage of the Study

5. Americas Metabolic Syndrome Market: Historic and Forecast (2018-2028)

  • 5.1 Americas Metabolic Syndrome Market: Snapshot
  • 5.2 Americas Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
  • 5.3 Americas Metabolic Syndrome Market: Key Factors
  • 5.4 Americas Metabolic Syndrome Market Segmentation: By Indication
    • 5.4.1 Americas Metabolic Syndrome Market, By Indication Overview
    • 5.4.2 Americas Metabolic Syndrome Market Size, By Insulin Resistance Syndrome, By Value, 2018H-2028F (USD Million & CAGR)
    • 5.4.3 Americas Metabolic Syndrome Market Size, By Hypercholesterolemia, By Value, 2018H-2028F (USD Million & CAGR)
    • 5.4.4 Americas Metabolic Syndrome Market Size, By Obesity Syndrome, By Value, 2018H-2028F (USD Million & CAGR)
    • 5.4.5 Americas Metabolic Syndrome Market Size, By Nonalcoholic steatohepatitis, By Value, 2018H-2028F (USD Million & CAGR)
    • 5.4.6 Americas Metabolic Syndrome Market Size, By Other Indications, By Value, 2018H-2028F (USD Million & CAGR)
  • 5.5 Americas Metabolic Syndrome Market Segmentation: By Molecule Type
    • 5.5.1 Americas Metabolic Syndrome Market, By Molecule Type Overview
    • 5.5.2 Americas Metabolic Syndrome Market Size, By Small Molecule, By Value, 2018H-2028F (USD Million & CAGR)
    • 5.5.3 Americas Metabolic Syndrome Market Size, By Protein, By Value, 2018H-2028F (USD Million & CAGR)
    • 5.5.4 Americas Metabolic Syndrome Market Size, By RNA/DNA, By Value, 2018H-2028F (USD Million & CAGR)
    • 5.5.5 Americas Metabolic Syndrome Market Size, By Other Molecules, By Value, 2018H-2028F (USD Million & CAGR)
  • 5.6 Americas Metabolic Syndrome Market Segmentation: By Route of Administration
    • 5.6.1 Americas Metabolic Syndrome Market, By Route of Administration Overview
    • 5.6.2 Americas Metabolic Syndrome Market Size, By Oral, By Value, 2018H-2028F (USD Million & CAGR)
    • 5.6.3 Americas Metabolic Syndrome Market Size, By Subcutaneous, By Value, 2018H-2028F (USD Million & CAGR)
    • 5.6.4 Americas Metabolic Syndrome Market Size, By Other ROA, By Value, 2018H-2028F (USD Million & CAGR)
  • 5.7 Americas Metabolic Syndrome Market Segmentation: By Country
    • 5.7.1 United States Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
      • 5.7.1.1 United States Metabolic Syndrome Market, By Indication
      • 5.7.1.2 United States Metabolic Syndrome Market, By Molecule Type
      • 5.7.1.3 United States Metabolic Syndrome Market, By Route of Administration
    • 5.7.2 Canada Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
      • 5.7.2.1 Canada Metabolic Syndrome Market, By Indication
      • 5.7.2.2 Canada Metabolic Syndrome Market, By Molecule Type
      • 5.7.2.3 Canada Metabolic Syndrome Market, By Route of Administration
    • 5.7.3 Rest of Americas Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
      • 5.7.3.1 Rest of Americas Metabolic Syndrome Market, By Indication
      • 5.7.3.2 Rest of Americas Metabolic Syndrome Market, By Molecule Type
      • 5.7.3.3 Rest of Americas Metabolic Syndrome Market, By Route of Administration

6. Europe Metabolic Syndrome Market: Historic and Forecast (2018-2028)

  • 6.1 Europe Metabolic Syndrome Market: Snapshot
  • 6.2 Europe Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
  • 6.3 Europe Metabolic Syndrome Market: Key Factors
  • 6.4 Europe Metabolic Syndrome Market Segmentation: By Indication
    • 6.4.1 Europe Metabolic Syndrome Market, By Indication Overview
    • 6.4.2 Europe Metabolic Syndrome Market Size, By Insulin Resistance Syndrome, By Value, 2018H-2028F (USD Million & CAGR)
    • 6.4.3 Europe Metabolic Syndrome Market Size, By Hypercholesterolemia, By Value, 2018H-2028F (USD Million & CAGR)
    • 6.4.4 Europe Metabolic Syndrome Market Size, By Obesity Syndrome, By Value, 2018H-2028F (USD Million & CAGR)
    • 6.4.5 Europe Metabolic Syndrome Market Size, By Nonalcoholic steatohepatitis, By Value, 2018H-2028F (USD Million & CAGR)
    • 6.4.6 Europe Metabolic Syndrome Market Size, By Other Indications, By Value, 2018H-2028F (USD Million & CAGR)
  • 6.5 Europe Metabolic Syndrome Market Segmentation: By Molecule Type
    • 6.5.1 Europe Metabolic Syndrome Market, By Molecule Type Overview
    • 6.5.2 Europe Metabolic Syndrome Market Size, By Small Molecule, By Value, 2018H-2028F (USD Million & CAGR)
    • 6.5.3 Europe Metabolic Syndrome Market Size, By Protein, By Value, 2018H-2028F (USD Million & CAGR)
    • 6.5.4 Europe Metabolic Syndrome Market Size, By RNA/DNA, By Value, 2018H-2028F (USD Million & CAGR)
    • 6.5.5 Europe Metabolic Syndrome Market Size, By Other Molecules, By Value, 2018H-2028F (USD Million & CAGR)
  • 6.6 Europe Metabolic Syndrome Market Segmentation: By Route of Administration
    • 6.6.1 Europe Metabolic Syndrome Market, By Route of Administration Overview
    • 6.6.2 Europe Metabolic Syndrome Market Size, By Oral, By Value, 2018H-2028F (USD Million & CAGR)
    • 6.6.3 Europe Metabolic Syndrome Market Size, By Subcutaneous, By Value, 2018H-2028F (USD Million & CAGR)
    • 6.6.4 Europe Metabolic Syndrome Market Size, By Other ROA, By Value, 2018H-2028F (USD Million & CAGR)
  • 6.7 Europe Metabolic Syndrome Market Segmentation: By Country
    • 6.7.1 France Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
      • 6.7.1.1 France Metabolic Syndrome Market, By Indication
      • 6.7.1.2 France Metabolic Syndrome Market, By Molecule Type
      • 6.7.1.3 France Metabolic Syndrome Market, By Route of Administration
    • 6.7.2 United Kingdom Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
      • 6.7.2.1 United Kingdom Metabolic Syndrome Market, By Indication
      • 6.7.2.2 United Kingdom Metabolic Syndrome Market, By Molecule Type
      • 6.7.2.3 United Kingdom Metabolic Syndrome Market, By Route of Administration
    • 6.7.3 Italy Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
      • 6.7.3.1 Italy Metabolic Syndrome Market, By Indication
      • 6.7.3.2 Italy Metabolic Syndrome Market, By Molecule Type
      • 6.7.3.3 Italy Metabolic Syndrome Market, By Route of Administration
    • 6.7.4 Spain Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
      • 6.7.4.1 Spain Metabolic Syndrome Market, By Indication
      • 6.7.4.2 Spain Metabolic Syndrome Market, By Molecule Type
      • 6.7.4.3 Spain Metabolic Syndrome Market, By Route of Administration
    • 6.7.5 Germany Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
      • 6.7.5.1 Germany Metabolic Syndrome Market, By Indication
      • 6.7.5.2 Germany Metabolic Syndrome Market, By Molecule Type
      • 6.7.5.3 Germany Metabolic Syndrome Market, By Route of Administration
    • 6.7.6 Rest of Europe Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
      • 6.7.6.1 Rest of Europe Metabolic Syndrome Market, By Indication
      • 6.7.6.2 Rest of Europe Metabolic Syndrome Market, By Molecule Type
      • 6.7.6.3 Rest of Europe Metabolic Syndrome Market, By Route of Administration

7. Asia-Pacific Metabolic Syndrome Market: Historic and Forecast (2018-2028)

  • 7.1 Asia-Pacific Metabolic Syndrome Market: Snapshot
  • 7.2 Asia-Pacific Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
  • 7.3 Asia-Pacific Metabolic Syndrome Market: Key Factors
  • 7.4 Asia-Pacific Metabolic Syndrome Market Segmentation: By Indication
    • 7.4.1 Asia-Pacific Metabolic Syndrome Market, By Indication Overview
    • 7.4.2 Asia-Pacific Metabolic Syndrome Market Size, By Insulin Resistance Syndrome, By Value, 2018H-2028F (USD Million & CAGR)
    • 7.4.3 Asia-Pacific Metabolic Syndrome Market Size, By Hypercholesterolemia, By Value, 2018H-2028F (USD Million & CAGR)
    • 7.4.4 Asia-Pacific Metabolic Syndrome Market Size, By Obesity Syndrome, By Value, 2018H-2028F (USD Million & CAGR)
    • 7.4.5 Asia-Pacific Metabolic Syndrome Market Size, By Nonalcoholic steatohepatitis, By Value, 2018H-2028F (USD Million & CAGR)
    • 7.4.6 Asia-Pacific Metabolic Syndrome Market Size, By Other Indications, By Value, 2018H-2028F (USD Million & CAGR)
  • 7.5 Asia-Pacific Metabolic Syndrome Market Segmentation: By Molecule Type
    • 7.5.1 Asia-Pacific Metabolic Syndrome Market, By Molecule Type Overview
    • 7.5.2 Asia-Pacific Metabolic Syndrome Market Size, By Small Molecule, By Value, 2018H-2028F (USD Million & CAGR)
    • 7.5.3 Asia-Pacific Metabolic Syndrome Market Size, By Protein, By Value, 2018H-2028F (USD Million & CAGR)
    • 7.5.4 Asia-Pacific Metabolic Syndrome Market Size, By RNA/DNA, By Value, 2018H-2028F (USD Million & CAGR)
    • 7.5.5 Asia-Pacific Metabolic Syndrome Market Size, By Other Molecules, By Value, 2018H-2028F (USD Million & CAGR)
  • 7.6 Asia-Pacific Metabolic Syndrome Market Segmentation: By Route of Administration
    • 7.6.1 Asia-Pacific Metabolic Syndrome Market, By Route of Administration Overview
    • 7.6.2 Asia-Pacific Metabolic Syndrome Market Size, By Oral, By Value, 2018H-2028F (USD Million & CAGR)
    • 7.6.3 Asia-Pacific Metabolic Syndrome Market Size, By Subcutaneous, By Value, 2018H-2028F (USD Million & CAGR)
    • 7.6.4 Asia-Pacific Metabolic Syndrome Market Size, By Other ROA, By Value, 2018H-2028F (USD Million & CAGR)
  • 7.7 Asia-Pacific Metabolic Syndrome Market Segmentation: By Country
    • 7.7.1 China Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
      • 7.7.1.1 China Metabolic Syndrome Market, By Indication
      • 7.7.1.2 China Metabolic Syndrome Market, By Molecule Type
      • 7.7.1.3 China Metabolic Syndrome Market, By Route of Administration
    • 7.7.2 Japan Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
      • 7.7.2.1 Japan Metabolic Syndrome Market, By Indication
      • 7.7.2.2 Japan Metabolic Syndrome Market, By Molecule Type
      • 7.7.2.3 Japan Metabolic Syndrome Market, By Route of Administration
    • 7.7.3 India Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
      • 7.7.3.1 India Metabolic Syndrome Market, By Indication
      • 7.7.3.2 India Metabolic Syndrome Market, By Molecule Type
      • 7.7.3.3 India Metabolic Syndrome Market, By Route of Administration
    • 7.7.4 Rest of Asia-Pacific Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
      • 7.7.4.1 Rest of Asia-Pacific Metabolic Syndrome Market, By Indication
      • 7.7.4.2 Rest of Asia-Pacific Metabolic Syndrome Market, By Molecule Type
      • 7.7.4.3 Rest of Asia-Pacific Metabolic Syndrome Market, By Route of Administration

8. Middle-East & Africa Metabolic Syndrome Market: Historic and Forecast (2018-2028)

  • 8.1 Middle-East & Africa Metabolic Syndrome Market: Snapshot
  • 8.2 Middle-East & Africa Metabolic Syndrome Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)
  • 8.3 Middle-East & Africa Metabolic Syndrome Market: Key Factors
  • 8.4 Middle-East & Africa Metabolic Syndrome Market Segmentation: By Indication
    • 8.4.1 Middle-East & Africa Metabolic Syndrome Market, By Indication Overview
    • 8.4.2 Middle-East & Africa Metabolic Syndrome Market Size, By Insulin Resistance Syndrome, By Value, 2018H-2028F (USD Million & CAGR)
    • 8.4.3 Middle-East & Africa Metabolic Syndrome Market Size, By Hypercholesterolemia, By Value, 2018H-2028F (USD Million & CAGR)
    • 8.4.4 Middle-East & Africa Metabolic Syndrome Market Size, By Obesity Syndrome, By Value, 2018H-2028F (USD Million & CAGR)
    • 8.4.5 Middle-East & Africa Metabolic Syndrome Market Size, By Nonalcoholic steatohepatitis, By Value, 2018H-2028F (USD Million & CAGR)
    • 8.4.6 Middle-East & Africa Metabolic Syndrome Market Size, By Other Indications, By Value, 2018H-2028F (USD Million & CAGR)
  • 8.5 Middle-East & Africa Metabolic Syndrome Market Segmentation: By Indication
    • 8.5.1 Middle-East & Africa Metabolic Syndrome Market, By Indication Overview
    • 8.5.2 Middle-East & Africa Metabolic Syndrome Market Size, By Small Molecule, By Value, 2018H-2028F (USD Million & CAGR)
    • 8.5.3 Middle-East & Africa Metabolic Syndrome Market Size, By Protein, By Value, 2018H-2028F (USD Million & CAGR)
    • 8.5.4 Middle-East & Africa Metabolic Syndrome Market Size, By RNA/DNA, By Value, 2018H-2028F (USD Million & CAGR)
    • 8.5.5 Middle-East & Africa Metabolic Syndrome Market Size, By Other Molecules, By Value, 2018H-2028F (USD Million & CAGR)
  • 8.6 Middle-East & Africa Metabolic Syndrome Market Segmentation: By Route of Administration
    • 8.6.1 Middle-East & Africa Metabolic Syndrome Market, By Route of Administration Overview
    • 8.6.2 Middle-East & Africa Metabolic Syndrome Market Size, By Oral, By Value, 2018H-2028F (USD Million & CAGR)
    • 8.6.3 Middle-East & Africa Metabolic Syndrome Market Size, By Subcutaneous, By Value, 2018H-2028F (USD Million & CAGR)
    • 8.6.4 Middle-East & Africa Metabolic Syndrome Market Size, By Other ROA, By Value, 2018H-2028F (USD Million & CAGR)

9. Market Dynamics

  • 9.1 Impact Assessment of Market Dynamics on the Global Metabolic Syndrome Market
  • 9.2 Drivers
  • 9.3 Restraints
  • 9.4 Trends

10. Industry Ecosystem Analysis

  • 10.1 Macro-Economic Factor Assessment
  • 10.3 Porter's Five Forces Model

11. Competitive Positioning

  • 11.1 Companies' Product Positioning
  • 11.2 Market Position Matrix
  • 11.3 Market Share Analysis of Metabolic Syndrome Market
  • 11.4 Company Profiles
    • 11.4.1 Novo Nordisk
    • 11.4.2 Eli Lilly and Company
    • 11.4.3 Takeda Pharmaceutical
    • 11.4.4 Sanofi
    • 11.4.5 AstraZeneca
    • 11.4.6 Amgen
    • 11.4.7 Merck Co., Inc.
    • 11.4.8 Johnson & Johnson
    • 11.4.9 Pfizer
    • 11.4.10 Abbott

List of Figures

List of Figures

  • Figure 1: Global obesity statistics 2022
  • Figure 2: Top marketed Therapeutics by NPV, USDm
  • Figure 3: Top Metabolic syndrome pipeline Therapeutics by NPV, USDm
  • Figure 4: Global Metabolic Syndrome Market Size, By Value, 2018-2022 (USD Million)
  • Figure 5: Global Metabolic Syndrome Market Size, By Value, 2023-2028 (USD Million)
  • Figure 6: Global Metabolic Syndrome Market Share, By Indication, 2028 (%)
  • Figure 7: Global Metabolic Syndrome Market Size, By Insulin Resistance Syndrome, By Value, 2018H-2028F (USD Million & CAGR)
  • Figure 8: Global Metabolic Syndrome Market Absolute Opportunity, By Insulin Resistance Syndrome, 2018-2028 (USD Million)
  • Figure 9: Global Metabolic Syndrome Market Size, By Hypercholesterolemia, By Value, 2018H-2028F (USD Million & CAGR)
  • Figure 10: Global Metabolic Syndrome Market Absolute Opportunity, By Hypercholesterolemia, 2018-2028 (USD Million)
  • Figure 11: Global Metabolic Syndrome Market Size, By Obesity Syndrome, By Value, 2018H-2028F (USD Million & CAGR)
  • Figure 12: Global Metabolic Syndrome Market Absolute Opportunity, By Obesity Syndrome, 2018-2028 (USD Million)
  • Figure 13: Global Metabolic Syndrome Market Size, By Nonalcoholic steatohepatitis, By Value, 2018H-2028F (USD Million & CAGR)
  • Figure 14: Global Metabolic Syndrome Market Absolute Opportunity, By Nonalcoholic steatohepatitis, 2018-2028 (USD Million)
  • Figure 15: Global Metabolic Syndrome Market Size, By Other Indications, By Value, 2018H-2028F (USD Million & CAGR)
  • Figure 16: Global Metabolic Syndrome Market Absolute Opportunity, By Other Indications, 2018-2028 (USD Million)
  • Figure 17: Global Metabolic Syndrome Market Size, By Small Molecule, By Value, 2018H-2028F (USD Million & CAGR)
  • Figure 18: Global Metabolic Syndrome Market Absolute Opportunity, By Small Molecule, 2018-2028 (USD Million)
  • Figure 19: Global Metabolic Syndrome Market Size, By Protein, By Value, 2018H-2028F (USD Million & CAGR)
  • Figure 20: Global Metabolic Syndrome Market Absolute Opportunity, By Protein, 2018-2028 (USD Million)
  • Figure 21: Global Metabolic Syndrome Market Size, By RNA/DNA, By Value, 2018H-2028F (USD Million & CAGR)
  • Figure 22: Global Metabolic Syndrome Market Absolute Opportunity, By RNA/DNA, 2018-2028 (USD Million)
  • Figure 23: Global Metabolic Syndrome Market Size, By Other Molecules, By Value, 2018H-2028F (USD Million & CAGR)
  • Figure 24: Global Metabolic Syndrome Market Absolute Opportunity, By Other Molecules, 2018-2028 (USD Million)
  • Figure 25: Global Metabolic Syndrome Market Size, By Oral , By Value, 2018H-2028F (USD Million & CAGR)
  • Figure 26: Global Metabolic Syndrome Market Absolute Opportunity, By Oral, 2018-2028 (USD Million)
  • Figure 27: Global Metabolic Syndrome Market Size, By Subcutaneous ,By Value, 2018H-2028F (USD Million & CAGR)
  • Figure 28: Global Metabolic Syndrome Market Absolute Opportunity, By Subcutaneous, 2018-2028 (USD Million)
  • Figure 29: Global Metabolic Syndrome Market Size, By Other ROA, By Value, 2018H-2028F (USD Million & CAGR)
  • Figure 30: Global Metabolic Syndrome Market Absolute Opportunity, By Other ROA, 2018-2028 (USD Million)
  • Figure 31: Americas Metabolic Syndrome Market Size, By Value, 2018H-2028F (USD Million)
  • Figure 32: Americas Metabolic Syndrome Market Share, By Indication, 2022 (%)
  • Figure 33: Americas Metabolic Syndrome Market, By Insulin Resistance Syndrome, By Value, 2018H-2028F (USD Million & CAGR)
  • Figure 34: Americas Metabolic Syndrome Market, By Hypercholesterolemia, By Value, 2018H-2028F (USD Million & CAGR)
  • Figure 35: Americas Metabolic Syndrome Market, By Obesity Syndrome, By Value, 2018H-2028F (USD Million & CAGR)
  • Figure 36: Americas Metabolic Syndrome Market, By Nonalcoholic steatohepatitis, By Value, 2018H-2028F (USD Million & CAGR)
  • Figure 37: Americas Metabolic Syndrome Market, By Other Indication, By Value, 2018H-2028F (USD Million & CAGR)
  • Figure 38: Americas Metabolic Syndrome Market, By Small Molecule, By Value, 2018H-2028F (USD Million & CAGR)
  • Figure 39: Americas Metabolic Syndrome Market, By Protein, By Value, 2018H-2028F (USD Million & CAGR)
  • Figure 40: Americas Metabolic Syndrome Market, By RNA/DNA, By Value, 2018H-2028F (USD Million & CAGR)
  • Figure 41: Americas Metabolic Syndrome Market, By Other Molecules, By Value, 2018H-2028F (USD Million & CAGR)
  • Figure 42: Americas Metabolic Syndrome Market, By Oral , By Value, 2018H-2028F (USD Million & CAGR)
  • Figure 43: Americas Metabolic Syndrome Market, By Subcutaneous, By Value, 2018H-2028F (USD Million & CAGR)
  • Figure 44: Americas Metabolic Syndrome Market, By Other ROA, By Value, 2018H-2028F (USD Million & CAGR)
  • Figure 45: United States Metabolic Syndrome Market, By Value, 2018-2028 (USD Million & CAGR)
  • Figure 46: United States Metabolic Syndrome Market Share, By Indication, By 2022 (USD Million)
  • Figure 47: United States Metabolic Syndrome Market Share, By Indication Type, By Value, 2022 (%)
  • Figure 48: United States Metabolic Syndrome Market Share, By Molecule Type, By Value, 2022 (%)
  • Figure 49: United States Metabolic Syndrome Market Share, By Route of Administration, By Value, 2022 (%)
  • Figure 50: Canada Metabolic Syndrome Market, By Value, 2018-2028 (USD Million & CAGR)
  • Figure 51: Canada Metabolic Syndrome Market Value, By Indication, 2022 (USD Million)
  • Figure 52: Canada Metabolic Syndrome Market Share, By Indication, By Value, 2022 (%)
  • Figure 53: Canada Metabolic Syndrome Market Share, By Molecule Type, By Value, 2022 (%)
  • Figure 54: Canada Metabolic Syndrome Market Share, By Route of Administration, By Value, 2022 (%)
  • Figure 55: Rest of Americas Metabolic Syndrome Market, By Value, 2018-2028 (USD Million & CAGR)
  • Figure 56: Rest of Americas Metabolic Syndrome Market Value, By Indication, 2022 (USD Million)
  • Figure 57: Rest of Americas Metabolic Syndrome Market Share, By Indication, By Value, 2022 (%)
  • Figure 58: Rest of Americas Metabolic Syndrome Market Share, By Molecule Type, By Value, 2022 (%)
  • Figure 59: Rest of Americas Metabolic Syndrome Market Share, By Route of Administration, By Value, 2022 (%)
  • Figure 60: Europe Metabolic Syndrome Market Size, By Value, 2018H-2028F (USD Million)
  • Figure 61: Europe Metabolic Syndrome Market Share, By Indication, 2022 (%)
  • Figure 62: Europe Metabolic Syndrome Market, By Insulin Resistance Syndrome, By Value, 2018H-2028F (USD Million & CAGR)
  • Figure 63: Europe Metabolic Syndrome Market, By Hypercholesterolemia, By Value, 2018H-2028F (USD Million & CAGR)
  • Figure 64: Europe Metabolic Syndrome Market, By Obesity Syndrome, By Value, 2018H-2028F (USD Million & CAGR)
  • Figure 65: Europe Metabolic Syndrome Market, By Nonalcoholic steatohepatitis, By Value, 2018H-2028F (USD Million & CAGR)
  • Figure 66: Europe Metabolic Syndrome Market, By Other Indication, By Value, 2018H-2028F (USD Million & CAGR)
  • Figure 67: Europe Metabolic Syndrome Market, By Small Molecule, By Value, 2018H-2028F (USD Million & CAGR)
  • Figure 68: Europe Metabolic Syndrome Market, By Protein, By Value, 2018H-2028F (USD Million & CAGR)
  • Figure 69: Europe Metabolic Syndrome Market, By RNA/DNA, By Value, 2018H-2028F (USD Million & CAGR)
  • Figure 70: Europe Metabolic Syndrome Market, By Other Molecules, By Value, 2018H-2028F (USD Million & CAGR)
  • Figure 71: Europe Metabolic Syndrome Market, By Oral , By Value, 2018H-2028F (USD Million & CAGR)
  • Figure 72: Europe Metabolic Syndrome Market, By Subcutaneous, By Value, 2018H-2028F (USD Million & CAGR)
  • Figure 73: Europe Metabolic Syndrome Market, By Other ROA, By Value, 2018H-2028F (USD Million & CAGR)
  • Figure 74: France Metabolic Syndrome Market, By Value, 2018-2028 (USD Million & CAGR)
  • Figure 75: France Metabolic Syndrome Market Value, By Indication, 2022 (USD Million)
  • Figure 76: France Metabolic Syndrome Market Share, By Indication, By Value, 2022 (%)
  • Figure 77: France Metabolic Syndrome Market Share, By Molecule Type, By Value, 2022 (%)
  • Figure 78: France Metabolic Syndrome Market Share, By Route of Administration, By Value, 2022 (%)
  • Figure 79: United Kingdom Metabolic Syndrome Market, By Value, 2018-2028 (USD Million & CAGR)
  • Figure 80: United Kingdom Metabolic Syndrome Market Value, By Indication, 2022 (USD Million)
  • Figure 81: United Kingdom Metabolic Syndrome Market Share, By Indication, By Value, 2022 (%)
  • Figure 82: United Kingdom Metabolic Syndrome Market Share, By Molecule Type, By Value, 2022 (%)
  • Figure 83: United Kingdom Metabolic Syndrome Market Share, By Route of Administration, By Value, 2022 (%)
  • Figure 84: Italy Metabolic Syndrome Market, By Value, 2018-2028 (USD Million & CAGR)
  • Figure 85: Italy Metabolic Syndrome Market Value, By Indication, 2022 (USD Million)
  • Figure 86: Italy Metabolic Syndrome Market Share, By Indication, By Value, 2022 (%)
  • Figure 87: Italy Metabolic Syndrome Market Share, By Molecule Type, By Value, 2022 (%)
  • Figure 88: Italy Metabolic Syndrome Market Share, By Route of Administration, By Value, 2022 (%)
  • Figure 89: Spain Metabolic Syndrome Market, By Value, 2018-2028 (USD Million & CAGR)
  • Figure 90: Spain Metabolic Syndrome Market Value, By Indication, 2022 (USD Million)
  • Figure 91: Spain Metabolic Syndrome Market Share, By Indication, By Value, 2022 (%)
  • Figure 92: Spain Metabolic Syndrome Market Share, By Molecule Type, By Value, 2022 (%)
  • Figure 93: Spain Metabolic Syndrome Market Share, By Route of Administration, By Value, 2022 (%)
  • Figure 94: Germany Metabolic Syndrome Market, By Value, 2018-2028 (USD Million & CAGR)
  • Figure 95: Germany Metabolic Syndrome Market Value, By Indication, 2022 (USD Million)
  • Figure 96: Germany Metabolic Syndrome Market Share, By Indication, By Value, 2022 (%)
  • Figure 97: Germany Metabolic Syndrome Market Share, By Molecule Type, By Value, 2022 (%)
  • Figure 98: Germany Metabolic Syndrome Market Share, By Route of Administration, By Value, 2022 (%)
  • Figure 99: Rest of Europe Metabolic Syndrome Market, By Value, 2018-2028 (USD Million & CAGR)
  • Figure 100: Rest of Europe Metabolic Syndrome Market Value, By Indication, 2022 (USD Million)
  • Figure 101: Rest of Europe Metabolic Syndrome Market Share, By Indication, By Value, 2022 (%)
  • Figure 102: Rest of Europe Metabolic Syndrome Market Share, By Molecule Type, By Value, 2022 (%)
  • Figure 103: Rest of Europe Metabolic Syndrome Market Share, By Route of Administration, By Value, 2022 (%)
  • Figure 104: Asia Pacific Metabolic Syndrome Market Size, By Value, 2018H-2028F (USD Million)
  • Figure 105: Asia Pacific Metabolic Syndrome Market Share, By Indication, 2022 (%)
  • Figure 106: Asia Pacific Metabolic Syndrome Market, By Insulin Resistance Syndrome, By Value, 2018H-2028F (USD Million & CAGR)
  • Figure 107: Asia Pacific Metabolic Syndrome Market, By Hypercholesterolemia, By Value, 2018H-2028F (USD Million & CAGR)
  • Figure 108: Asia Pacific Metabolic Syndrome Market, By Obesity Syndrome, By Value, 2018H-2028F (USD Million & CAGR)
  • Figure 109: Asia Pacific Metabolic Syndrome Market, By Nonalcoholic steatohepatitis, By Value, 2018H-2028F (USD Million & CAGR)
  • Figure 110: Asia Pacific Metabolic Syndrome Market, By Other Indication, By Value, 2018H-2028F (USD Million & CAGR)
  • Figure 111: Asia Pacific Metabolic Syndrome Market, By Small Molecule, By Value, 2018H-2028F (USD Million & CAGR)
  • Figure 112: Asia Pacific Metabolic Syndrome Market, By Protein, By Value, 2018H-2028F (USD Million & CAGR)
  • Figure 113: Asia Pacific Metabolic Syndrome Market, By RNA/DNA, By Value, 2018H-2028F (USD Million & CAGR)
  • Figure 114: Asia Pacific Metabolic Syndrome Market, By Other Molecules, By Value, 2018H-2028F (USD Million & CAGR)
  • Figure 115: Asia Pacific Metabolic Syndrome Market, By Oral , By Value, 2018H-2028F (USD Million & CAGR)
  • Figure 116: Asia Pacific Metabolic Syndrome Market, By Subcutaneous, By Value, 2018H-2028F (USD Million & CAGR)
  • Figure 117: Asia Pacific Metabolic Syndrome Market, By Other ROA, By Value, 2018H-2028F (USD Million & CAGR)
  • Figure 118: China Metabolic Syndrome Market, By Value, 2018-2028 (USD Million & CAGR)
  • Figure 119: China Metabolic Syndrome Market Value, By Indication, 2022 (USD Million)
  • Figure 120: China Metabolic Syndrome Market Share, By Indication, By Value, 2022 (%)
  • Figure 121: China Metabolic Syndrome Market Share, By Molecule Type, By Value, 2022 (%)
  • Figure 122: China Metabolic Syndrome Market Share, By Route of Administration, By Value, 2022 (%)
  • Figure 123: Japan Metabolic Syndrome Market, By Value, 2018-2028 (USD Million & CAGR)
  • Figure 124: Japan Metabolic Syndrome Market Value, By Indication, 2022 (USD Million)
  • Figure 125: Japan Metabolic Syndrome Market Share, By Indication, By Value, 2022 (%)
  • Figure 126: Japan Metabolic Syndrome Market Share, By Molecule Type, By Value, 2022 (%)
  • Figure 127: Japan Metabolic Syndrome Market Share, By Route of Administration, By Value, 2022 (%)
  • Figure 128: India Metabolic Syndrome Market, By Value, 2018-2028 (USD Million & CAGR)
  • Figure 129: India Metabolic Syndrome Market Value, By Indication, 2022 (USD Million)
  • Figure 130 India Metabolic Syndrome Market Share, By Indication, By Value, 2022 (%)
  • Figure 131 India Metabolic Syndrome Market Share, By Molecule Type, By Value, 2022 (%)
  • Figure 132: India Metabolic Syndrome Market Share, By Route of Administration, By Value, 2022 (%)
  • Figure 133: Rest of Asia Pacific Metabolic Syndrome Market, By Value, 2018-2028 (USD Million & CAGR)
  • Figure 134: Rest of Asia Pacific Metabolic Syndrome Market Value, By Indication, 2022 (USD Million)
  • Figure 135: Rest of Asia Pacific Metabolic Syndrome Market Share, By Indication, By Value, 2022 (%)
  • Figure 136: Rest of Asia Pacific Metabolic Syndrome Market Share, By Molecule Type, By Value, 2022 (%)
  • Figure 137: Rest of Asia Pacific Metabolic Syndrome Market Share, By Route of Administration, By Value, 2022 (%)
  • Figure 138: Middle East & Africa Metabolic Syndrome Market Size, By Value, 2018H-2028F (USD Million)
  • Figure 139: Middle East & Africa Metabolic Syndrome Market Share, By Indication, 2022 (%)
  • Figure 140: Middle East & Africa Metabolic Syndrome Market, By Insulin Resistance Syndrome, By Value, 2018H-2028F (USD Million & CAGR)
  • Figure 141: Middle East & Africa Metabolic Syndrome Market, By Hypercholesterolemia, By Value, 2018H-2028F (USD Million & CAGR)
  • Figure 142: Middle East & Africa Metabolic Syndrome Market, By Obesity Syndrome, By Value, 2018H-2028F (USD Million & CAGR)
  • Figure 143: Middle East & Africa Metabolic Syndrome Market, By Nonalcoholic steatohepatitis, By Value, 2018H-2028F (USD Million & CAGR)
  • Figure 144: Middle East & Africa Metabolic Syndrome Market, By Other Indication, By Value, 2018H-2028F (USD Million & CAGR)
  • Figure 145: Middle East & Africa Metabolic Syndrome Market, By Small Molecule, By Value, 2018H-2028F (USD Million & CAGR)
  • Figure 146: Middle East & Africa Metabolic Syndrome Market, By Protein, By Value, 2018H-2028F (USD Million & CAGR)
  • Figure 147: Middle East & Africa Metabolic Syndrome Market, By RNA/DNA, By Value, 2018H-2028F (USD Million & CAGR)
  • Figure 148: Middle East & Africa Metabolic Syndrome Market, By Other Molecules, By Value, 2018H-2028F (USD Million & CAGR)
  • Figure 149: Middle East & Africa Metabolic Syndrome Market, By Oral , By Value, 2018H-2028F (USD Million & CAGR)
  • Figure 150: Middle East & Africa Metabolic Syndrome Market, By Subcutaneous, By Value, 2018H-2028F (USD Million & CAGR)
  • Figure 151: Middle East & Africa Metabolic Syndrome Market, By Other ROA, By Value, 2018H-2028F (USD Million & CAGR)
  • Figure 152: Global Impact of Drivers and Restraints
  • Figure 153: Market Share of Leading Companies in Metabolic Syndrome Market, 2022E (%)
  • Figure 154: Novo Nordisk Revenues, 2020-2022 (USD Million)
  • Figure 155: Novo Nordisk Revenues, By Geographic Segments, 2022 (%)
  • Figure 156: Novo Nordisk Revenue , By Therapeutic Area, 2022 (%)
  • Figure 157: Eli Lilly and Company Revenues, 2020-2022 (USD Million)
  • Figure 158: Eli Lilly and Company Revenues, By Geographic Segments, 2022 (%)
  • Figure 159: Eli Lilly and Company Revenue , By Therapeutic Area, 2022 (%)
  • Figure 160: Takeda Pharmaceuticals Revenues, 2019-2021 (USD Million)
  • Figure 161: Takeda Pharmaceuticals Revenues, By Geographic Segments, 2021 (%)
  • Figure 162: Takeda Pharmaceuticals Revenue , By Business Segments, 2021 (%)
  • Figure 163: Sanofi Revenues, 2020-2022 (USD Million)
  • Figure 164: Sanofi Revenues, By Geographic Segments, 2022 (%)
  • Figure 165: Sanofi Revenue , By Business Segments, 2022 (%)
  • Figure 166: AstraZeneca PLC Revenues, 2020-2022 (USD Million)
  • Figure 167: AstraZeneca PLC Revenues, By Geographic Segments, 2022 (%)
  • Figure 168: AstraZeneca PLC Revenue , By Business Segments, 2022 (%)
  • Figure 169: Amgen, Inc. Revenues, 2020-2022 (USD Million)
  • Figure 170: Amgen, Inc. Revenues, By Geographic Segments, 2022 (%)
  • Figure 171: Amgen, Inc. Revenue , By Products, 2022 (%)
  • Figure 172: Merck & Co., Inc. Revenues, 2020-2022 (USD Million)
  • Figure 173: Merck & Co., Inc. Revenues, By Geographic Segments, 2022 (%)
  • Figure 174: Merck & Co., Inc. Revenue , By Business Segments, 2022 (%)
  • Figure 175: Johnson & Johnson Revenues, 2020-2022 (USD Million)
  • Figure 176: Johnson & Johnson Revenues, By Geographic Segments, 2022 (%)
  • Figure 177: Johnson & Johnson Revenue , By Business Segments, 2022 (%)
  • Figure 178: Pfizer Revenues, 2020-2022 (USD Million)
  • Figure 179: Pfizer Revenues, By Business Segments, 2022 (%)
  • Figure 180: Pfizer Inc. Revenue , By Geographical Segments, 2022 (%)
  • Figure 181: Abbott Laboratories Revenues, 2020-2022 (USD Million)
  • Figure 182: Abbott Laboratories Revenues, By Geographic Segments, 2022 (%)
  • Figure 183: Abbott Laboratories Revenue , By Business Segments, 2022 (%)
  • Figure 177: Johnson & Johnson Revenue , By Business Segments, 2022 (%)
  • Figure 178: Pfizer Revenues, 2020-2022 (USD Million)
  • Figure 179: Pfizer Revenues, By Business Segments, 2022 (%)
  • Figure 180: Pfizer Inc. Revenue , By Geographical Segments, 2022 (%)
  • Figure 181: Abbott Laboratories Revenues, 2020-2022 (USD Million)
  • Figure 182: Abbott Laboratories Revenues, By Geographic Segments, 2022 (%)
  • Figure 183: Abbott Laboratories Revenue , By Business Segments, 2022 (%)

List of Tables

Table A1: Global Impact of Macro Economic Factors, By Region

Table A2: Metabolic Syndrome Therapeutics in Pipeline

Table A3: United States Metabolic Syndrome Market, By Indication, By Value, 2018-2022 (USD Million)

Table A4: United States Metabolic Syndrome Market, By Indication, By Value, 2023-2028 (USD Million)

Table A5: United States Metabolic Syndrome Market, By Molecule Type, By Value, 2018-2022 (USD Million)

Table A6: United States Metabolic Syndrome Market, By Molecule Type, By Value, 2023-2028 (USD Million)

Table A7: United States Metabolic Syndrome Market, By Route of Administration, By Value, 2018-2022 (USD Million)

Table A8: United States Metabolic Syndrome Market, By Route of Administration, By Value, 2023-2028 (USD Million)

Table A9: Canada Metabolic Syndrome Market, By Indication, By Value, 2018-2022 (USD Million)

Table A10: Canada Metabolic Syndrome Market, By Indication, By Value, 2023-2028 (USD Million)

Table A11: Canada Metabolic Syndrome Market, By Molecule Type, By Value, 2018-2022 (USD Million)

Table A12: Canada Metabolic Syndrome Market, By Molecule Type, By Value, 2023-2028 (USD Million)

Table A13: Canada Metabolic Syndrome Market, By Route of Administration, By Value, 2018-2022 (USD Million)

Table A14: Canada Metabolic Syndrome Market, By Route of Administration, By Value, 2023-2028 (USD Million)

Table A15: Rest of Americas Metabolic Syndrome Market, By Indication, By Value, 2018-2022 (USD Million)

Table A16: Rest of Americas Metabolic Syndrome Market, By Indication, By Value, 2023-2028 (USD Million)

Table A17: Rest of Americas Metabolic Syndrome Market, By Molecule Type, By Value, 2018-2022 (USD Million)

Table A18: Rest of Americas Metabolic Syndrome Market, By Molecule Type, By Value, 2023-2028 (USD Million)

Table A19: Rest of Americas Metabolic Syndrome Market, By Route of Administration, By Value, 2018-2022 (USD Million)

Table A20: Rest of Americas Metabolic Syndrome Market, By Route of Administration, By Value, 2023-2028 (USD Million)

Table A21: France Metabolic Syndrome Market, By Indication, By Value, 2018-2022 (USD Million)

Table A22: France Metabolic Syndrome Market, By Indication, By Value, 2023-2028 (USD Million)

Table A23: France Metabolic Syndrome Market, By Molecule Type, By Value, 2018-2022 (USD Million)

Table A24: France Metabolic Syndrome Market, By Molecule Type, By Value, 2023-2028 (USD Million)

Table A25: France Metabolic Syndrome Market, By Route of Administration, By Value, 2018-2022 (USD Million)

Table A26: France Metabolic Syndrome Market, By Route of Administration, By Value, 2023-2028 (USD Million)

Table A27: United Kingdom Metabolic Syndrome Market, By Indication, By Value, 2018-2022 (USD Million)

Table A28: United Kingdom Metabolic Syndrome Market, By Indication, By Value, 2023-2028 (USD Million)

Table A29: United Kingdom Metabolic Syndrome Market, By Molecule Type, By Value, 2018-2022 (USD Million)

Table A30: United Kingdom Metabolic Syndrome Market, By Molecule Type, By Value, 2023-2028 (USD Million)

Table A31: United Kingdom Metabolic Syndrome Market, By Route of Administration, By Value, 2018-2022 (USD Million)

Table A32: United Kingdom Metabolic Syndrome Market, By Route of Administration, By Value, 2023-2028 (USD Million)

Table A33: Italy Metabolic Syndrome Market, By Indication, By Value, 2018-2022 (USD Million)

Table A34: Italy Metabolic Syndrome Market, By Indication, By Value, 2023-2028 (USD Million)

Table A35: Italy Metabolic Syndrome Market, By Molecule Type, By Value, 2018-2022 (USD Million)

Table A36: Italy Metabolic Syndrome Market, By Molecule Type, By Value, 2023-2028 (USD Million)

Table A37: Italy Metabolic Syndrome Market, By Route of Administration, By Value, 2018-2022 (USD Million)

Table A38: Italy Metabolic Syndrome Market, By Route of Administration, By Value, 2023-2028 (USD Million)

Table A39: Spain Metabolic Syndrome Market, By Indication, By Value, 2018-2022 (USD Million)

Table A40: Spain Metabolic Syndrome Market, By Indication, By Value, 2023-2028 (USD Million)

Table A41: Spain Metabolic Syndrome Market, By Molecule Type, By Value, 2018-2022 (USD Million)

Table A42: Spain Metabolic Syndrome Market, By Molecule Type, By Value, 2023-2028 (USD Million)

Table A43: Spain Metabolic Syndrome Market, By Route of Administration, By Value, 2018-2022 (USD Million)

Table A44: Spain Metabolic Syndrome Market, By Route of Administration, By Value, 2023-2028 (USD Million)

Table A45: Germany Metabolic Syndrome Market, By Indication, By Value, 2018-2022 (USD Million)

Table A46: Germany Metabolic Syndrome Market, By Indication, By Value, 2023-2028 (USD Million)

Table A47: Germany Metabolic Syndrome Market, By Molecule Type, By Value, 2018-2022 (USD Million)

Table A48: Germany Metabolic Syndrome Market, By Molecule Type, By Value, 2023-2028 (USD Million)

Table A49: Germany Metabolic Syndrome Market, By Route of Administration, By Value, 2018-2022 (USD Million)

Table A50: Germany Metabolic Syndrome Market, By Route of Administration, By Value, 2023-2028 (USD Million)

Table A51: Rest of Europe Metabolic Syndrome Market, By Indication, By Value, 2018-2022 (USD Million)

Table A52: Rest of Europe Metabolic Syndrome Market, By Indication, By Value, 2023-2028 (USD Million)

Table A53: Rest of Europe Metabolic Syndrome Market, By Molecule Type, By Value, 2018-2022 (USD Million)

Table A54: Rest of Europe Metabolic Syndrome Market, By Molecule Type, By Value, 2023-2028 (USD Million)

Table A55: Rest of Europe Metabolic Syndrome Market, By Route of Administration, By Value, 2018-2022 (USD Million)

Table A56: Rest of Europe Metabolic Syndrome Market, By Route of Administration, By Value, 2023-2028 (USD Million)

Table A57: China Metabolic Syndrome Market, By Indication, By Value, 2018-2022 (USD Million)

Table A58: China Metabolic Syndrome Market, By Indication, By Value, 2023-2028 (USD Million)

Table A59: China Metabolic Syndrome Market, By Molecule Type, By Value, 2018-2022 (USD Million)

Table A60: China Metabolic Syndrome Market, By Molecule Type, By Value, 2023-2028 (USD Million)

Table A61: China Metabolic Syndrome Market, By Route of Administration, By Value, 2018-2022 (USD Million)

Table A62: China Metabolic Syndrome Market, By Route of Administration, By Value, 2023-2028 (USD Million)

Table A63: Japan Metabolic Syndrome Market, By Indication, By Value, 2018-2022 (USD Million)

Table A64: Japan Metabolic Syndrome Market, By Indication, By Value, 2023-2028 (USD Million)

Table A65: Japan Metabolic Syndrome Market, By Molecule Type, By Value, 2018-2022 (USD Million)

Table A66: Japan Metabolic Syndrome Market, By Molecule Type, By Value, 2023-2028 (USD Million)

Table A67: Japan Metabolic Syndrome Market, By Route of Administration, By Value, 2018-2022 (USD Million)

Table A68: Japan Metabolic Syndrome Market, By Route of Administration, By Value, 2023-2028 (USD Million)

Table A69: India Metabolic Syndrome Market, By Indication, By Value, 2018-2022 (USD Million)

Table A70: India Metabolic Syndrome Market, By Indication, By Value, 2023-2028 (USD Million)

Table A71: India Metabolic Syndrome Market, By Molecule Type, By Value, 2018-2022 (USD Million)

Table A72: India Metabolic Syndrome Market, By Molecule Type, By Value, 2023-2028 (USD Million)

Table A73: India Metabolic Syndrome Market, By Route of Administration, By Value, 2018-2022 (USD Million)

Table A74: India Metabolic Syndrome Market, By Route of Administration, By Value, 2023-2028 (USD Million)

Table A75: Rest of Asia Pacific Metabolic Syndrome Market, By Indication, By Value, 2018-2022 (USD Million)

Table A76: Rest of Asia Pacific Metabolic Syndrome Market, By Indication, By Value, 2023-2028 (USD Million)

Table A77: Rest of Asia Pacific Metabolic Syndrome Market, By Molecule Type, By Value, 2018-2022 (USD Million)

Table A78: Rest of Asia Pacific Metabolic Syndrome Market, By Molecule Type, By Value, 2023-2028 (USD Million)

Table A79: Rest of Asia Pacific Metabolic Syndrome Market, By Route of Administration, By Value, 2018-2022 (USD Million)

Table A80: Rest of Asia Pacific Metabolic Syndrome Market, By Route of Administration, By Value, 2023-2028 (USD Million)

Table A81: Novo Nordisk Key Financials, 2020-2022

Table A82: Eli Lilly and Company Key Financials, 2020-2022

Table A83: Takeda Pharmaceuticals Key Financials, 2020-2022

Table A84: Sanofi Key Financials, 2020-2022

Table A85: AstraZeneca PLC Key Financials, 2020-2022

Table A86: Amgen, Inc. Key Financials, 2020-2022

Table A87: Merck & Co., Inc. Key Financials, 2020-2022

Table A88: Johnson & Johnson Key Financials, 2020-2022

Table A89: Pfizer Key Financials, 2020-2022

Table A90: Abbott Laboratories Key Financials, 2020-2022